Dynamics of in vivo immune remodeling in Ph+ all patients receiving frontline ponatinib and blinatumomab therapy
: Tyrosine kinase inhibitor (TKI)-based chemotherapy-free strategies, combining dasatinib or ponatinib with the bispeci fi c monoclonal antibody blinatumomab, have substantially improved the response rates and outcome of adult patients with Philadel-phia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1 – 7]...